Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | -35.69%2.15B | -36.85%1.14B | -10.67%5.77B | -4.67%4.53B | 0.17%3.34B | 2.86%1.8B | 0.45%6.46B | -2.40%4.76B | -2.10%3.33B | 0.92%1.75B |
| Operating income | -35.69%2.15B | -10.67%5.77B | 0.17%3.34B | 0.45%6.46B | -2.10%3.33B | |||||
| Cost of sales | 15.96%-1.26B | ---- | -0.76%-2.86B | ---- | -7.71%-1.5B | ---- | 0.80%-2.84B | ---- | 5.23%-1.39B | ---- |
| Operating expenses | 15.96%-1.26B | -0.76%-2.86B | -7.71%-1.5B | 0.80%-2.84B | 5.23%-1.39B | |||||
| Gross profit | -51.70%890.35M | -50.63%509M | -19.65%2.91B | 2.4B | -5.21%1.84B | 2.28%1.03B | 1.46%3.62B | 0.27%1.94B | -1.08%1.01B | |
| Selling expenses | 53.39%-353.36M | ---- | 25.39%-1.14B | ---- | 17.67%-758.06M | ---- | 7.69%-1.53B | ---- | 1.33%-920.79M | ---- |
| Administrative expenses | 6.80%-130.82M | ---- | 2.96%-299.21M | ---- | -1.94%-140.37M | ---- | -8.25%-308.32M | ---- | 9.07%-137.7M | ---- |
| Research and development expenses | 0.19%-136.26M | ---- | 8.21%-265.97M | ---- | 1.61%-136.52M | ---- | -11.83%-289.75M | ---- | -11.51%-138.75M | ---- |
| Impairment and provision | 1,176.09%1.49M | ---- | -659.66%-6.49M | ---- | 58.93%-138K | ---- | 123.84%1.16M | ---- | 87.97%-336K | ---- |
| -Other impairment is provision | 1,176.09%1.49M | ---- | -659.66%-6.49M | ---- | 58.93%-138K | ---- | 123.84%1.16M | ---- | 87.97%-336K | ---- |
| Special items of operating profit | 143.12%99.46M | ---- | 1.06%150.33M | ---- | -9.69%40.91M | ---- | 128.25%148.76M | ---- | 57.78%45.3M | ---- |
| Operating profit | -56.33%370.86M | -18.02%1.34B | 7.17%849.28M | 15.11%1.64B | 4.78%792.48M | |||||
| Financing income | -15.38%20.11M | ---- | -2.48%38.49M | ---- | -4.12%23.77M | ---- | -20.90%39.47M | ---- | 0.41%24.79M | ---- |
| Financing cost | 13.17%-54.84M | ---- | -1.17%-126.88M | ---- | -3.98%-63.16M | ---- | -42.11%-125.41M | ---- | -60.39%-60.75M | ---- |
| Share of profits of associates | -5.70%12.98M | ---- | -13.45%26.49M | ---- | -2.90%13.76M | ---- | 121.99%30.61M | ---- | 132.99%14.17M | ---- |
| Earning before tax | -57.61%349.11M | -19.07%1.28B | 6.87%823.65M | 13.18%1.58B | 2.87%770.7M | |||||
| Tax | 53.20%-58.91M | ---- | 18.99%-206M | ---- | -3.85%-125.87M | ---- | -21.32%-254.28M | ---- | 12.01%-121.19M | ---- |
| After-tax profit from continuing operations | -58.41%290.2M | -19.08%1.08B | 7.43%697.79M | 11.75%1.33B | 6.22%649.51M | |||||
| Earning after tax | -58.41%290.2M | -19.08%1.08B | 7.43%697.79M | 11.75%1.33B | 6.22%649.51M | |||||
| Minority profit | -44.49%6.69M | ---- | 35.48%14.46M | ---- | 10.60%12.05M | ---- | -84.00%10.67M | ---- | -73.70%10.89M | ---- |
| Profit attributable to shareholders | -58.66%283.51M | -59.52%168.47M | -19.53%1.06B | -2.75%919M | 7.38%685.74M | 14.64%416.15M | 17.44%1.32B | 13.04%945M | 12.03%638.61M | 19.80%363M |
| Basic earnings per share | -58.39%0.0962 | -19.34%0.3582 | 7.58%0.2312 | 18.08%0.4441 | 12.75%0.2149 | |||||
| Diluted earnings per share | -58.26%0.0962 | -19.09%0.3581 | 7.76%0.2305 | 17.68%0.4426 | 12.22%0.2139 | |||||
| Currency Unit | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD |
| Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- | -- |
| Auditor | -- | -- | KPMG | -- | -- | -- | KPMG | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.